Priming of an immune response
AssigneeUniversity of Copenhagen
InventorsPeter Johannes Holst, Allan Randrup Thomsen, Jan Pravsgaard Christensen, Mirjana Grujic
Life of this patent
Estimating the term…
Abstract
The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.
Claims32
A nucleic acid construct comprising sequences encoding
- a. at least one variant of an invariant chain operatively linked to
- b. at least one antigenic protein or peptide or an antigenic fragment of said protein or peptide,
- wherein four LRMK amino acid residues of a KEY region of the at least one variant of the invariant chain are deleted or substituted with other amino acid residues.
(canceled)
(canceled)
-12. (canceled)
(canceled)
(canceled)
-28. (canceled)
-38. (canceled)
-44. (canceled)
-50. (canceled)
-63. (canceled)
-68. (canceled)
A nucleic acid construct comprising sequences encoding
- a. at least one invariant chain altered from its wild type sequence operatively linked to
- b. at least one antigenic protein or peptide or an antigenic fragment of said protein or peptide,
- wherein said nucleic acid construct is used for priming a bacterial vaccine.
An adenoviral vector comprising sequences encoding a variant of an invariant chain operatively linked to lymphocytic choriomeningitis virus glycoprotein, wherein the variant of an invariant chain is operatively linked at the terminal part after the last residue of the variant of an invariant chain to the lymphocytic choriomeningitis virus glycoprotein, wherein the variant of an invariant chain consists of residues 1-201 of SEQ ID NO:
- 4 and wherein the adenoviral vector is derived from adenovirus serotype 5.
Dependencies are inferred from the claim text.